Viewing nowCombinationTeramet XR Controlled-release Tablet 50/1000 mg
Sitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Teragen Etex Co., Ltd.

MFDS item code 202202013 · Approved 2022.05.13 · Insurance code 698504780
Improvement of glycemic control in type 2 diabetes mellitus
This drug is used as an adjunct to diet and exercise for the treatment of type 2 diabetes to help control blood sugar levels. Sitagliptin and metformin work together to effectively lower blood sugar levels and support the management of diabetes, assisting patients in achieving better blood glucose control.
In antidiabetic therapy, the dose of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This drug should be taken once daily with a meal, preferably in the evening, with gradual dose escalation to reduce gastrointestinal adverse reactions caused by metformin. To maintain its extended-release properties, this drug must be swallowed whole and must not be split, crushed, ground, or chewed. The dose of this drug 100/1000 mg extended-release tablets is 1 tablet once daily. Patients taking this drug 50/500 mg extended-release tablets or 50/1000 mg extended-release tablets should take 2 tablets together once daily. 1. Patients not currently receiving metformin: For patients with no prior experience with antidiabetic drug therapy whose blood glucose cannot be adequately controlled with monotherapy, or for whom adequate blood glucose control cannot be achieved with sitagliptin monotherapy, the initial total daily dose of this drug is sitagliptin 100 mg and metformin 1000 mg. If adequate blood glucose control cannot be achieved with the initial dose, the dose may be gradually increased up to the maximum recommended daily dose of metformin 2000 mg to reduce gastrointestinal adverse reactions caused by metformin. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this drug (see Precautions for Use, 2. Do not administer to the following patients). 2. Patients receiving metformin: - The recommended initial total daily dose of this drug for patients whose blood glucose cannot be adequately controlled with metformin monotherapy is sitagliptin 100 mg and the patient's current metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this drug may start at their current doses of sitagliptin and metformin. - Patients taking immediate-release tablets at a current metformin dose of 850 mg or 1000 mg twice daily may start with 2 tablets of this drug 50/1000 mg extended-release tablets once daily. 3. Patients whose blood glucose cannot be adequately controlled with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial total daily dose of this drug is sitagliptin 100 mg, and the initial dose of metformin should be based on the patient's blood glucose level and current dose. The dose should be gradually increased to reduce gastrointestinal adverse reactions caused by metformin. When administered in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). Patients with renal impairment This drug may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and <60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and <60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Since the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this drug. The maximum recommended dose of metformin is 1000 mg daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl <45 mL/min or eGFR <45 mL/min/1.73m2, this drug should be discontinued immediately. Patients with hepatic impairment This drug should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Do not administer to the following patients).
This drug is used for the treatment of diabetes and contains two components: sitagliptin and metformin. There is a risk of hypersensitivity reactions; if symptoms such as skin rash or difficulty breathing occur, discontinue use immediately and consult a doctor. There is a risk of pancreatitis, so if sudden abdominal pain, vomiting, or fever occurs, consult a physician immediately. This drug should not be administered to patients with impaired kidney function, serious infections, heart failure, or acute myocardial infarction. If a procedure using iodinated contrast agents is planned, this drug should be discontinued for a period before and after the procedure to avoid potential kidney problems. It is recommended that pregnant or nursing women not take this medication for safety reasons. Hypoglycemia may occur, so caution is advised when skipping meals or engaging in vigorous exercise, and the risk of hypoglycemia may be increased if taken with other antidiabetic medications. This drug is not recommended for patients with impaired liver function, and regular liver and kidney function tests should be conducted. A rare complication known as lactic acidosis may occur, characterized by excessive buildup of lactic acid in the body, with symptoms such as muscle pain, weakness, difficulty breathing, and abdominal pain. If these occur, notify medical staff immediately. Alcohol consumption may increase the risk of lactic acidosis; therefore, it is advisable to avoid drinking while on this medication. Regular monitoring of blood sugar, kidney function, and hematological tests is required while taking this drug, and consult a physician immediately if any unusual symptoms arise. Additionally, there may be other medications that interact with this drug, so inform your doctor or pharmacist of any other medications you are taking. Elderly patients frequently have decreased kidney function, so extreme caution is needed during use, and regular testing is recommended. In case of overdose, seek medical care immediately to receive appropriate treatment, and blood dialysis may be performed if necessary.
Not everyone experiences these, and they can vary from person to person.
Store this medication in a tightly sealed container to prevent exposure to air or moisture. It is best to maintain the storage temperature between 1 degree and 30 degrees Celsius to preserve the medication's efficacy and safety for a prolonged period.
Bright green, double convex, oval-shaped controlled-release film-coated tablet
28 tablets/bottle, 56 tablets/bottle, 200 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Teragen Etex Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Korea Hutech Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.